Apogee reports 75% quarterly and 85% biannual EASI-75 maintenance in Phase 2 trial
Apogee Therapeutics reported 52-week maintenance of EASI-75 in its Phase 2 trial of zumilokibart, with 75% (3-month) and 85% (6-month) dosing arms retaining at least 75% lesion reduction. vIGA 0/1 responses held in 86% and 78% of patients, with deepening efficacy and a safety profile in line with class norms.
1. Phase 2 Part A evaluation
Apogee Therapeutics enrolled moderate-to-severe atopic dermatitis patients in the APEX Part A trial, administering 360mg of zumilokibart with 3-month and 6-month maintenance intervals to assess durability of response over 52 weeks.
2. Efficacy outcomes
At Week 52, 75% of patients in the 3-month arm and 85% in the 6-month arm maintained EASI-75 lesion reduction. Validated Investigator’s Global Assessment 0/1 response was sustained in 86% (3-month) and 78% (6-month) of patients, with continued deepening across itch and lesion endpoints.
3. Safety profile and next steps
Zumilokibart was well tolerated, with noninfective conjunctivitis, upper respiratory tract infection and nasopharyngitis as the most common adverse events. Part B 16-week induction data are expected in 2Q 2026, supporting initiation of Phase 3 trials in 2H 2026 and a potential commercial launch in 2029.